BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Phase I Study of BMS-275183 (Oral Taxane) Given on a Daily Schedule in Combination With Esomeprazole (Nexium) in Patients With Advanced Cancer

Phase 1

Terminated

Conditions: Cancer

First Posted Date: 2006-06-02

Last Posted Date: 2010-03-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 36

Registration Number: NCT00332748

Locations: 🇳🇱
Local Institution, Amsterdam, Netherlands

A Phase I Study of BMS-690514 in Patients With Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Cancer
Tumor

Interventions: Drug: BMS-690514

First Posted Date: 2006-05-24

Last Posted Date: 2011-01-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 89

Registration Number: NCT00329004

Locations: 🇪🇸
Local Institution, Barcelona, Spain
🇺🇸
Indiana University Med Center, Indianapolis, Indiana, United States
🇺🇸
The University Of Texas Md Anderson Cancer Center, Houston, Texas, United States

A Phase I Dose-Escalation Study of BMS-641988 in Patients With Castration-Resistant Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: AR Antagonist (BMS-641988)

First Posted Date: 2006-05-17

Last Posted Date: 2011-01-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 54

Registration Number: NCT00326586

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
University Of Wisconsin Hospital And Clinics Laboratory, Madison, Wisconsin, United States
🇺🇸
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States

Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant Women

Phase 1

Completed

Conditions: HIV Infection

Interventions: Drug: Atazanavir + Ritonavir + Combivir

First Posted Date: 2006-05-17

Last Posted Date: 2011-11-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 69

Registration Number: NCT00326716

Locations: 🇺🇸
Triple O Medical Services, P.A., West Palm Beach, Florida, United States
🇺🇸
Women's Hospital Of Texas, Houston, Texas, United States
🇿🇦
Local Institution, Westdene, Gauteng, South Africa

A Phase I Study of a Single Dose of Radio-labeled BMS-275183 in Patients With Advanced Cancer

Phase 1

Terminated

Conditions: Cancer

First Posted Date: 2006-05-16

Last Posted Date: 2010-03-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 6

Registration Number: NCT00326131

Locations: 🇺🇸
Local Institution, San Antonio, Texas, United States

Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer

Phase 1

Completed

Conditions: Neoplasm Metastasis
Prostate Cancer

Interventions: Drug: MDX-010

First Posted Date: 2006-05-10

Last Posted Date: 2014-08-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 75

Registration Number: NCT00323882

Locations: 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States

and more 10 locations

Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma

Phase 3

Completed

Conditions: Melanoma

Interventions: Drug: Placebo
Drug: Ipilimumab
Drug: Dacarbazine

First Posted Date: 2006-05-10

Last Posted Date: 2014-11-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 681

Registration Number: NCT00324155

Locations: 🇺🇸
Thompson Cancer Survival Center, Knoxville, Tennessee, United States
🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States
🇺🇸
St Joseph Oncology Inc, Saint Joseph, Missouri, United States

and more 30 locations

Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase

Phase 1

Withdrawn

Conditions: Myeloid Leukemia, Chronic, Chronic-Phase

First Posted Date: 2006-05-10

Last Posted Date: 2016-02-17

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT00324077

Locations: 🇺🇸
Local Institution, New York, New York, United States

Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib

Phase 2

Terminated

Conditions: Leukemia, Myeloid, Chronic

Interventions: Drug: Dasatinib
Drug: Imatinib

First Posted Date: 2006-05-03

Last Posted Date: 2013-10-30

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 52

Registration Number: NCT00320190

Locations: 🇬🇧
Local Institution, Leeds, North Yorkshire, United Kingdom

A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer

Phase 2

Completed

Conditions: Pulmonary Embolism
Cancer
Thrombosis

Interventions: Drug: Placebo
Drug: Apixaban

First Posted Date: 2006-05-03

Last Posted Date: 2016-08-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 130

Registration Number: NCT00320255

Locations: 🇺🇸
Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸
Univ. Of Southern Calif. /Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Mount Sinai School Of Medicine, New York, New York, United States

and more 6 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy